Is autophagy actually REQUIRED for the mammalian lifespan benefit?
The gap
Autophagy (the cell's self-cleanup process) is widely assumed to be why blocking mTOR extends lifespan, but that's only been directly shown in flies and worms, plus one mouse study that boosted autophagy a different way. Nobody has tested what happens to rapamycin's lifespan benefit in mice that can't do autophagy at all.
What changed since this question was written
Nothing has answered the question, but the experiment as proposed turns out not to be runnable. Inducible whole-body Atg7 deletion in an adult mouse limits survival to two or three months through neurodegeneration and infection, plus fatal fasting hypoglycaemia (Karsli-Uzunbas, Cancer Discov 2014, PMID 24875857); a lifespan study needs about three years. A null result would be unreadable — no benefit, or an animal that died of something rapamycin cannot fix — and chronic rapamycin also inhibits mTORC2, so failure in an Atg7 knockout would not implicate autophagy cleanly either. In flies, rapamycin already acts through autophagy and translation in parallel (Bjedov, Cell Metab 2010, PMID 20074526), so the expected mammalian answer is partly, which a survival curve cannot resolve.
What is still open
Necessity, still untested in any mammal. The mammalian evidence runs one way only: raising autophagy extends life (Becn1-F121A knock-in, Fernandez, Nature 2018, PMID 29849149; Atg5 overexpression, +17.2% median, Pyo, Nat Commun 2013, PMID 23939249). Sufficiency is shown; necessity is not.
The hypothesis
Educated guess: autophagy is actually required – mice that can't perform autophagy should get no lifespan benefit from rapamycin, even though the drug still works everywhere else.
How it could be tested
Occlusion rather than ablation. Does rapamycin still extend lifespan in Becn1-F121A mice, which already carry maximal basal autophagy and are healthy? Full additivity means autophagy carries little of rapamycin's benefit; occlusion means it carries that much. No sick animals are needed and the line already exists. Supporting designs: tissue-restricted Atg7 deletion, which survives into old age (Yuan, Aging Cell 2020, PMID 32212304), and autophagy-hypomorphic rather than null backgrounds. One caveat on the Becn1 line: its longevity phenotype is abolished by a chronic high-phosphate diet (Shi, FASEB J 2020, PMID 31908069), so diet must be controlled.
Related studies
| Year | Evidence | Study |
|---|---|---|
| 2010 | A | Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster BJE2010 Feeding rapamycin extended fly lifespan through autophagy and reduced translation, and worked even in flies already on a lifespan-maximizing diet. |
| 2008 | A | A role for autophagy in the extension of lifespan by dietary restriction in C. elegans HAN2008 Makes autophagy a necessary step between dietary restriction and a longer life, not a side effect of it: blocking autophagy genes abolishes the lifespan extension produced both by dietary restriction and by TOR inhibition. The paper is equally careful about what autophagy cannot do on its own, because autophagy still runs in animals lacking DAF-16/FOXO and yet those animals are not long-lived. Boundary: worms; necessity was shown, sufficiency was not. |
| 2013 | A | Overexpression of Atg5 in mice activates autophagy and extends lifespan PYO2013 Mice engineered with extra copies of the autophagy gene Atg5 lived 17% longer and were leaner and more insulin-sensitive. |
| 2016 | A | Cardioprotection and lifespan extension by the natural polyamine spermidine EIS2016 The mammalian follow-up to EIS2009 and the reason the spermidine branch matters for human health claims: oral spermidine extends mouse lifespan, reduces cardiac hypertrophy and preserves diastolic function, and the protection disappears in mice whose cardiomyocytes lack Atg5, which makes autophagy necessary rather than merely correlated. Boundary: the human part is a dietary questionnaire correlated with blood pressure and cardiovascular incidence, so it is observational and does not carry the causal claim the mouse data carry. |
| 2009 | A | Induction of autophagy by spermidine promotes longevity EIS2009 The opening paper of the caloric-restriction-mimetic branch: a natural polyamine whose level falls with human age extends lifespan in yeast, flies, worms and human immune cells, and the effect depends on autophagy. In ageing yeast this works through inhibition of histone acetyltransferases, which raises autophagy gene expression. The paper did not measure mTOR, so whether this route bypasses mTOR is not tested here. Boundary: no mammalian lifespan data in this paper. |
Revision history
ShowHide
- 2026-09-04: The basis previously read 'No study tests whether...', an absence claim about the whole literature; now scoped to this corpus.
- 2026-09-21: MEL2003 was cited as the worm evidence. It tested bec-1 in daf-2 mutants (the insulin/IGF-1 pathway, not TOR and not dietary restriction), so it did not support the claim; HAN2008 replaced it.
- 2026-10-03: EIS2016 added - mouse evidence that cardiomyocyte Atg5 is required for spermidine-induced cardioprotection and lifespan extension, addressing the necessity-of-autophagy question for a geroprotector other than rapamycin.
- 2026-10-03: EIS2009 added - invertebrate necessity evidence that autophagy is required for a lifespan-extending intervention, leaving the mammalian necessity question and the rapamycin-specific case untouched (yeast, fly, worm and human immune cells; no mammalian lifespan data).
← All open questions · Frontier questions
Thank you. Your answer was counted anonymously.